## **Shannon Chang**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/572178/publications.pdf

Version: 2024-02-01

567281 477307 46 913 15 29 citations h-index g-index papers 46 46 46 1270 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 126-135.	4.4	32
2	Indications, functional and quality of life outcomes of new pouch creation during re-do ileal pouch anal anastomosis: A comparative study with existing pouch salvage. Surgery, 2022, 171, 287-292.	1.9	3
3	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2022, 7, 69-95.	8.1	41
4	Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy. Inflammatory Bowel Diseases, 2022, 28, 1826-1832.	1.9	21
5	Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2021, 66, 369-380.	2.3	52
6	From the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area. Inflammatory Bowel Diseases, 2021, 27, 662-666.	1.9	26
7	Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States. Crohn's & Colitis 360, 2021, 3, .	1.1	14
8	Comparative Evaluation of Conventional Stool Testing and Multiplex Molecular Panel in Outpatients With Relapse of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1634-1640.	1.9	4
9	Implementation of an Inpatient IBD Service Is Associated with Improvement in Quality of Care and Long-Term Outcomes. Digestive Diseases and Sciences, 2021, 66, 3753-3759.	2.3	3
10	Medical treatment of pouchitis: a guide for the clinician. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110233.	3.2	8
11	Crohn Disease Prognostication With Semiautomatic Dual-Energy Computed Tomography Enterography–Derived Iodine Density. Journal of Computer Assisted Tomography, 2021, 45, 171-176.	0.9	1
12	Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients. Gastroenterology, 2021, 160, 1679-1693.	1.3	40
13	Inter-reader agreement of the Society of Abdominal Radiology-American Gastroenterological Association (SAR-AGA) consensus reporting for key phenotypes at MR enterography in adults with Crohn disease: impact of radiologist experience. Abdominal Radiology, 2021, 46, 5095-5104.	2.1	2
14	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International leal Pouch Consortium. The Lancet Gastroenterology and Hepatology, 2021, 6, 826-849.	8.1	69
15	Crohn Disease Active Inflammation Assessment with Iodine Density from Dual-Energy CT Enterography: Comparison with Histopathologic Analysis. Radiology, 2021, 301, 144-151.	7.3	18
16	Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials. Digestive Diseases and Sciences, 2021, 66, 1631-1638.	2.3	12
17	Mobile Health in IBD: Enhancing Care, One Phone at a Time. Inflammatory Bowel Diseases, 2020, 26, 163-166.	1.9	4
18	Alvimopan for the Prevention of Postoperative Ileus in Inflammatory Bowel Disease Patients. Digestive Diseases and Sciences, 2020, 65, 1164-1171.	2.3	6

#	Article	IF	Citations
19	You forgot a staple! A septal defect in the ileal pouch–anal anastomosis. Gastrointestinal Endoscopy, 2020, 91, 715-717.	1.0	0
20	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 872-880.e1.	4.4	16
21	Outbreak in New York! Measles Hepatitis. American Journal of Gastroenterology, 2020, 115, 502-502.	0.4	0
22	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 669-681.	3.7	48
23	Novel Dual-Energy Computed Tomography Enterography Iodine Density Maps Provide Unique Depiction of Crohn Disease Activity. Journal of Computer Assisted Tomography, 2020, 44, 772-779.	0.9	7
24	Systematic review with metaâ€analysis: a history of smoking is not associated with a higher risk of pouchitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1117-1124.	3.7	4
25	Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature. Inflammatory Bowel Diseases, 2020, 26, 971-973.	1.9	31
26	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2952-2961.e8.	4.4	48
27	A clinical and radiographic model to predict surgery for acute small bowel obstruction in Crohn's disease. Abdominal Radiology, 2020, 45, 2663-2668.	2.1	5
28	First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Current Gastroenterology Reports, 2020, 22, 7.	2.5	24
29	Adjunctive Pharmacotherapy Use in Patients With Ileal Pouch-Anal Anastomosis (IPAA). Crohn's & Colitis 360, 2020, 2, .	1.1	1
30	Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study. Turkish Journal of Gastroenterology, 2020, 31, 676-680.	1.1	0
31	S0786â€∫Update on Laboratory Parameters Related to Monitoring in Patients With Ulcerative Colitis Treated With Tofacitinib in the OCTAVE Open-Label, Long-Term Extension Study. American Journal of Gastroenterology, 2020, 115, S402-S402.	0.4	0
32	S0215â€fGender and Racial Disparities in Colorectal Cancer Incidence and Survival: A Population-Based Study. American Journal of Gastroenterology, 2020, 115, S68-S68.	0.4	0
33	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory Bowel Diseases, 2019, 25, 1854-1861.	1.9	11
34	649â€fMultiplex Polymerase Chain Reaction-Based Stool Testing Results in Less Endoscopy in Outpatients With Inflammatory Bowel Disease Compared to Conventional Stool Testing. American Journal of Gastroenterology, 2019, 114, S379-S381.	0.4	0
35	648â€fOutpatients With Inflammatory Bowel Disease Are More Likely to Have Viral and Multiple Enteric Infections Identified on Multiplex PCR Pathogen Panel Testing. American Journal of Gastroenterology, 2019, 114, S379-S379.	0.4	0
36	655â€fTumor Necrosis Factor Antagonists Are Superior to Ustekinumab and Vedolizumab for the Prevention of Postoperative Recurrence in Adult Crohn's Disease. American Journal of Gastroenterology, 2019, 114, S384-S384.	0.4	2

#	Article	IF	CITATIONS
37	647â€∱Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Vedolizumab or Ustekinumab. American Journal of Gastroenterology, 2019, 114, S378-S379.	0.4	0
38	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	4.4	60
39	732â€∱Laboratory Parameters Related to Monitoring in Patients With Ulcerative Colitis Treated With Tofacitinib for up to 3 Years in the OCTAVE Open-Label, Long-Term Extension Study. American Journal of Gastroenterology, 2019, 114, S431-S431.	0.4	2
40	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.4	119
41	The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease. European Journal of Clinical Pharmacology, 2018, 74, 1361-1362.	1.9	5
42	Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease. Current Treatment Options in Gastroenterology, 2017, 15, 53-70.	0.8	11
43	Optimizing pharmacologic management of inflammatory bowel disease. Expert Review of Clinical Pharmacology, 2017, 10, 595-607.	3.1	27
44	Making the Cut: An Isolated Filiform Polyp. Clinical Gastroenterology and Hepatology, 2016, 14, e95.	4.4	1
45	Disease monitoring in inflammatory bowel disease. World Journal of Gastroenterology, 2015, 21, 11246.	3.3	134
46	Diagnosis of Neoplasia in Barrett's Esophagus using Vital-dye Enhanced Fluorescence Imaging. Journal of Visualized Experiments, 2014, , .	0.3	1